Multimodale Therapie des resektablen Ösophaguskarzinoms

Zusammenfassung

Das Ösophaguskarzinom ist eine lebensbedrohliche Erkrankung – trotz interdisziplinärer Therapiestrategien liegt die 5-Jahres-Überlebensrate unter 50 %. Dieser Artikel gibt einen Überblick über das stadiengerechte Vorgehen und die Vor- und Nachteile der aktuell in Europa praktiziertenmultimodalen Therapie des Ösophaguskarzinoms.

Publikationsverlauf

Artikel online veröffentlicht:
28. Oktober 2021

• Literatur

• 1 Gupta B, Kumar N. Worldwide incidence, mortality and time trends for cancer of the oesophagus. Eur J Cancer Prev 2017; 26: 107-118
• 2 Onkopedia.com. Leitlinie Ösophaguskarzinom. 2021 Im Internet (Stand: 10.05.2021): http://www.onkopedia.com/de/onkopedia/guidelines/oesophaguskarzinom/@@guideline/html/index.html
• 3 Robert Koch-Institut. Krebs in Deutschland für 2013/2014. Gemeinsame Publikation des Zentrums für Krebsregisterdaten und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. 11. Ausgabe. 2017. Im Internet (Stand: 10.05.2021): http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2017 / krebs_in_deutschland_2017.pdf?__blob=publicationFile
• 4 Lordick F, Mariette C, Haustermans K. et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 05) v50-v57
• 5 Siewert JR, Holscher AH, Becker K. et al. [Cardia cancer: attempt at a therapeutically relevant classification]. Chirurg 1987; 58: 25-32
• 6 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus, Langversion 2.0; 2018. AWMF Registernummer: 021/023OL. Im Internet (Stand: 10.05.2021): http://www.leitlinienprogramm-onkologie.de/leitlinien/oesophaguskarzinom/
• 7 Wittekind C. [2010 TNM system: on the 7th edition of TNM classification of malignant tumors]. Pathologe 2010; 31: 331-332
• 8 Pech O, May A, Manner H. et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146: 652-660.e1
• 9 Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T. et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: 829-854
• 10 Good Clinical Practice Network, Universitätsklinikum Hamburg-Eppendorf. Neoplastischer Barrett-Ösophagus: Endoskopische stückweise vs. En-bloc-Resektion. Dezember 2020. Im Internet (Stand: 11.05.2021): http://ichgcp.net/de/clinical-trials-registry/NCT03427346
• 11 Sgourakis G, Gockel I, Lang H. Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review. World J Gastroenterol 2013; 19: 1424-1437
• 12 Shapiro J, van Lanschot JJB, Hulshof MCCM. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16: 1090-1098
• 13 Wang K, Ren Y, Ma Z. et al. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis. Cancer Manag Res 2019; 11: 3009-3020
• 14 Lorenzen S, Biederstadt A, Ronellenfitsch U. et al. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction – a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 2020; 20: 886
• 15 Hoeppner J, Lordick F, Brunner T. et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 2016; 16: 503
• 16 Kelly RJ, Ajani JA, Kuzdzal J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191-1203
• 17 Low DE, Kuppusamy MK, Alderson D. et al. Benchmarking complications associated with esophagectomy. Ann Surg 2019; 269: 291-298
• 18 Chen Y, Lu Y, Wang Y. et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus 2014; 27: 134-140
• 19 ClinicalTrials.gov. Combination of Chemoradiation With Immunotherapy in Inoperable oesophageal Cancer (CRUCIAL). November 2019. Im Internet (Stand: 10.05.2021): http://clinicaltrials.gov/ct2/show/NCT03437200
• 20 Grimminger PP, Fuchs HF. [Minimally invasive and robotic-assisted surgical management of upper gastrointestinal cancer]. Chirurg 2017; 88: 1017-1023
• 21 Grimminger PP, Tagkalos E, Hadzijusufovic E. et al. Change from hybrid to fully minimally invasive and robotic esophagectomy is possible without compromises. Thorac Cardiovasc Surg 2019; 67: 589-596
• 22 Akiyama H, Tsurumaru M, Udagawa H. et al Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220: 364-372 ; discussion 372–373
• 23 Hölscher AH, Bollschweiler E, Beckurts KT. et al. [Extent of radical surgery in cardia carcinoma – esophagectomy or gastrectomy?]. Langenbecks Arch Chir Suppl Kongressbd 1996; 113: 169-172
• 24 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Magenkarzinom, Langversion 2.01 (Konsultationsfassung); 2019. AWMF Registernummer: 032/009OL. Im Internet (Stand: 10.05.2021): http://www.leitlinienprogramm-onkologie.de/leitlinien/magenkarzinom/
• 25 Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
• 26 Moehler M, Shitara K, Garrido M. et al Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1 L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 ; Abstract LBA6_PR
• 27 Kato K, Sun J, Shah MA. et al Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE‑590 study. Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 ; Abstract LBA8_PR
• 28 Kato K, Cho BC, Takahashi M. et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION‑3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 1506-1517
• 29 Kojima T, Shah MA, Muro K. et al. Randomized Phase III KEY-NOTE‑181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol 2020; 38: 4138-4148